
Codexis (CDXS) Stock Forecast & Price Target
Codexis (CDXS) Analyst Ratings
Bulls say
Codexis Inc. demonstrates a strong positive outlook due to its innovative ECO Synthesis manufacturing platform, which enhances the production of RNAi therapeutics through an enzymatic route, potentially lowering production costs for drug developers. The company's proven track record of producing inclisiran using multiple methods indicates flexibility and reliability, essential for attracting potential customers and fostering strategic partnerships. Additionally, the heightened enthusiasm and discussions surrounding the platform at recent industry events suggest a strong market interest, positioning Codexis to capitalize on the growing demand for siRNA therapies.
Bears say
Codexis Inc faces significant challenges regarding its production capacity for RNAi therapeutics, which raises concerns about the company's ability to meet increasing market demand. The ongoing development of the ECO Synthesis platform introduces further investment risks due to the potential for production delays or program failures. Additionally, existing cumbersome and environmentally detrimental manufacturing methods hinder scalability and efficiency, while intensified competition from both established and new players could impact Codexis's market position if it successfully develops its RNA manufacturing capabilities.
This aggregate rating is based on analysts' research of Codexis and is not a guaranteed prediction by Public.com or investment advice.
Codexis (CDXS) Analyst Forecast & Price Prediction
Start investing in Codexis (CDXS)
Order type
Buy in
Order amount
Est. shares
0 shares